Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Merging molecular glue and inhibitor for degrading GSPT1 and inhibiting mTOR proteins concurrently

ABSTRACT: U87 cells were treated with the 300 nM YB-3-17 and MLN0128 for 4 h before cell lysis. GSPT1 stood out as the most down-regulated targets. Quantitative analysis of the cells after treatment.

ORGANISM(S): Homo Sapiens

SUBMITTER: Yu Rao

PROVIDER: PXD052389 | iProX | Fri May 17 00:00:00 BST 2024

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [MCF7 and T47D RNAseq]

Project description:We performed RNA sequencing on T47D and MCF7 cells, both parental and abema- or abema/fulvestrant- resistant, treated with either control vehicle or 300 nM (MCF7) or 100 nM (T47D) INX-315 for 7 days

2023-11-22 | GSE243150 | GEO

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [OVCAR3 RNAseq]

Project description:We performed RNA sequencing on OVCAR3 parental cells treated with either control vehicle for 4 days or 300 nM INX-315 for 7 days.

2023-11-22 | GSE243152 | GEO

Transcriptome analysis of inhibitor-treated schistosome female

Project description:Transcriptional profiling of S. mansoni adult females treated with Herbimycin A (4.5 µM ) or TGF beta receptor type I kinase inhibitor (TRIKI, 300 nM) or a combined treatment with both inhibitors (Herbimycin A 4.5µM and TRIKI 300nM) vs. Non-treated S.mansoni adult females (DMSO during 48h)

2013-05-30 | GSE39732 | GEO

Exploring the molecular mechanism of artesunate intervening in glioma based on DNA methylation sequencing technology

Project description:Whole gene methylation profiles of U87 and U251 glioma cells before and after artesunate treatment, Infinium MethylationEPIC BeadChip, samples including 3 U87 cell normal group, 3 U251 cell normal group, 3 artesunate treated U87 cell group, U251 cell group was treated with 3 artesunate.

2022-10-18 | GSE215784 | GEO

Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently.

Project description: Not available

| S-EPMC8648895 | biostudies-literature

Chk1 inhiitors decrease the expressions of STAT3 downstream target genes in multiple myeloma cells

Project description:Study #1: U266 cells were treated with 100 nM PF477736 for 4 hr. Study #2: U266 cells were treated with 100 nM PF477736 for 16 hr. Study #3: KAS/6-1 cells were treated with 50 nM PF477736 or 300 nM CEP3891 for 2 hr.

2022-12-01 | GSE174548 | GEO

GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis.

Project description: Not available

| S-EPMC4322980 | biostudies-literature

Site-Specific Competitive Kinase Inhibitor Target Profiling Using Phosphonate Affinity Tags

Project description:Protein kinases are prime targets for drug development due to their involvement in various cancers. However, selective inhibition of kinases, while avoiding off-target effects remains a significant challenge for the development of protein kinase inhibitors. Activity-based protein profiling (ABPP), in combination with pan-kinase activity-based probes (ABPs) and mass spectrometry-based proteomics, enables the identification of kinase drug targets. Here, we extend existing ABPP strategies for kinase profiling with a site-specific analysis, allowing for protein kinase inhibitor target engagement profiling with amino acid specificity. The site-specific approach involves highly efficient enrichment of ABP-labeled peptides, resulting in a less complex peptide matrix, straightforward data analysis, and the screening of over ~100 kinase active sites in a single LC-MS run. The use of both trypsin and pepsin in parallel to generate the ABP-labeled peptides considerably expanded the coverage of kinases and exact binding sites. Using the site-specific strategy to examine the on- and off-targets of the Ephrin receptor (Eph) B4 inhibitor NVP-BHG712 showed binding to EphA2 with an IC50 of 17 nM (95% CI 10 - 28 nM) and EphB4 with an IC50 of 20.2 nM (95% CI 13.7 - 30.4 nM). Next to the known targets, EphA2 and EphB4, NVP-BHG712 bound to the discoidin domain-containing receptor 1 (DDR1) with an IC50 of 2.1 nM (95% CI 1.3 - 3.4 nM), suggesting that a DDR1-targeting regioisomer of NVP-BHG712 was analyzed. The promiscuity of XO44 toward ATP-binding pockets on other proteins facilitated the screening of an additional 475 sites, revealing inosine-5’-monophosphate dehydrogenase 2 (IMPDH2) as an off-target. Therefore, the presented approach, which can be fully automated with liquid handling platforms, provides a straightforward, valuable strategy for competitive site-specific kinase inhibitor target profiling.

2025-05-07 | PXD058749 | Pride

Comparative study of a mTOR inhibitor, a pan-PI3K inhibitor and a dual PI3K/mTOR inhibitor in MCL

Project description:Phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway activation contributes to mantle cell lymphoma (MCL) pathogenesis and drug resistance. However, the use of mTOR inhibitors as single agents have shown limited clinical efficacy in relation with drug activation of feedback loops. Selective PI3K inhibition or dual PI3K/mTOR catalytic inhibition are different therapeutic approaches developed to achieve effective pathway blockage. Here, we evaluated the antitumor activity of a mTOR inhibitor, a pan-PI3K inhibitor and a dual PI3K/mTOR inhibitor in primary MCL cells. We found that dual PI3K/mTOR inhibitor modulated angiogenesis, tumor invasiveness and cytokine signaling compared to a mTOR inhibitor and a pan-PI3K inhibitor in MCL. We used microarrays to compare the effect of these three compounds in MCL and identified distinct classes of down-regulated genes modulated by each compound. Global RNA expression in primary cells from two MCL patients treated with a mTOR inhibitor, a pan-PI3K inhibitor and a dual PI3K/mTOR inhibitor for 8 hours

2013-12-14 | E-GEOD-53309 | biostudies-arrayexpress

Transcriptome analysis of inhibitor-treated schistosome female

Project description:Transcriptional profiling of S. mansoni adult females treated with Herbimycin A (4.5 ÂµM ) or TGF beta receptor type I kinase inhibitor (TRIKI, 300 nM) or a combined treatment with both inhibitors (Herbimycin A 4.5ÂµM and TRIKI 300nM) vs. Non-treated S.mansoni adult females (DMSO during 48h) Two conditions (treated vs. Non-treated) with three biological samples of treated worms (Herbimycin, TRIKI or Herb+TRIKI) and in parallel other three biological samples of non-treated worms (DMSO) for each treatment condition. For each sample (three treated and three non-treated for each inhibitor combination) were performed two technical replicas.

2013-05-30 | E-GEOD-39732 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data